Three Firms Guide Catalent's $140M Pharma Biz Buy

By Darcy Reddan · July 3, 2018, 6:22 PM EDT

Drug development and delivery company Catalent Inc. said on Tuesday that it has agreed to acquire Juniper Pharmaceuticals Inc. in a deal that carries an equity value of approximately $139.6 million...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Recent Articles By Darcy

November 08, 2019
Chinese Startups, US Biotechs Price IPOs Raising $121M
November 05, 2019
Cannabis-Focused Blank Check Co. Prices Upsized $120M IPO
October 30, 2019
Baker McKenzie, Paul Hastings Steer $530M Daelim Latex Buy
October 29, 2019
Pepper Hamilton Guides Medical Device Maker's $60M IPO
October 08, 2019
Choate Hall & Stewart Guides Sverica's $450M Fund Closing
October 03, 2019
SmileDirectClub Hit With Investor Suit Over $1.3B IPO
September 25, 2019
Hogan Lovells Adds Corporate Pro To Life Sciences Group
September 12, 2019
Simpson Thacher Steers Genomics' $390M Upsized IPO
September 12, 2019
Skadden-Led SmileDirectClub Prices $1.3B IPO Above Range
September 09, 2019
Datadog Leads IPO Flurry Expected To Raise $729M Combined